BlueCross BlueShield of Tennessee Medical Policy Manual

OnabotulinumtoxinA

NDC CODE(S)

00023-1145-XX Botox 100 UNIT SOLR (ALLERGAN)

 

00023-3921-XX Botox 200 UNIT SOLR (ALLERGAN)

DESCRIPTION

Botulinum toxin, produced by the bacterium Clostridium botulinum, is one of the most potent naturally occurring neurotoxins known.  It induces chemodenervation by first binding to acceptors on motor nerve terminals.  It then enters the terminals and blocks the release of acetylcholine and other neurotransmitters at the neuromuscular junction.  This renders smooth and striated muscles incapable of contraction.  Acetylcholine also mediates the sympathetic innervation of the sweat glands, explaining how botulinum toxin disrupts the cholinergic outflow to the skin and halts glandular secretion.

The minute amount of toxin used clinically produces only partial, localized chemical denervation with transient results.  Over time, axons generate temporary sprouts which release acetylcholine and the original nerve terminal is eventually re-established, ending the toxin’s therapeutic activity.

Seven antigenic-specific serotypes of botulinum toxin have been identified, types A, B, C-1, D, E, F and G, but only botulinum toxin types A and B are commercially available.  These commercial preparations of the two serotypes (three of serotype A and one of serotype B) vary widely in potency and dosage.  They have been given different names to reinforce these differences and to prevent medication errors.  It is emphasized that the use and dosage of different formulations of botulinum toxin is not interchangeable.

This policy addresses only onabotulinumtoxinA, commercially available as Botox®.

POLICY

MEDICAL APPROPRIATENESS

INITIAL APPROVAL

RENEWAL CRITERIA

Note:  When initiating treatment, the lowest recommended dose should be used. In treating adult patients for one or more indications, the maximum cumulative dose should not exceed 400 Units in a 3 month (12 week) interval.

Unless otherwise stated, re-treatment should occur no sooner than 12 weeks from the prior injection.

INDICATION(S) DOSAGE & ADMINISTRATION
Blepharospasm 1.25-2.5 Units (0.05—0.1 ml per site) injected into each of 3 sites per affected eye every three months. There appears to be little benefit obtainable from injecting more than 5 Units per site. The effect of treatment lasts an average of 12 weeks. Cumulative dose in 30 days should not exceed 200 units
Cervical Dystonia 198 Units to 300 Units divided among the affected muscles. No more than 50 Units per site. May re-treat in 12 weeks.
Strabismus Based on muscle(s) affected, 1.25-2.5 Units in any one muscle initially. Subsequent doses may be increased up to two-fold compared to previously administered dose. No more than 25 U in any one muscle for recurrent cases. The effect of treatment usually lasts about 12 weeks.
Achalasia 100 Units (20-25 Units per quadrant) per administration, dose may be repeated in 6 months
Upper Limb Spasticity Dosing in initial and sequential treatment sessions should be tailored to the individual based on the size, number and location of muscles involved, severity of spasticity, the presence of local muscle weakness, the patient’s response to previous treatment, or adverse event history with BOTOX. In clinical trials, doses ranging from 75 Units to 400 Units were divided among selected muscles at a given treatment session, no sooner than every 12 weeks.
Lower Limb Spasticity 300 to 400 Units divided among 5 muscle groups (gastrocnemius, soleus, tibialis posterior, flexor hallucis longus, and flexor digitorum longus), no sooner than every 12 weeks
Chronic Migraine 155 Units administered intramuscularly (IM) as 0.1 mL (5 Units) injections per each site. Injections should be divided across 7 specific head/neck muscle areas. Recommended re-treatment schedule is every 12 weeks.
Focal Spasticity-cerebral palsy patients, 2-18 yrs 4 Units/kg IM (up to 200 Units) divided into 2 injections in the affected leg every 12 weeks
Severe primary axillary hyperhidrosis 50 Units intradermally per axilla every 16 weeks
Sialorrhea 15-40 Units in the parotid gland injected in two places and 10-15 Units in the submandibular glands (total dose from 50-100 Units per patient/administration).  Repeat in 3 months if needed.
Neurogenic bladder/Detrusor overactivity 200 Units per treatment injected into the detrusor muscle using 30 injections (6.7 units each). Re-inject no sooner than 12 weeks from the prior bladder injection
Overactive Bladder (OAB) 100 Units per treatment injected into the detrusor muscle using 20 injections (5 units each). Re-inject no sooner than 12 weeks from the prior bladder injection.
Palmar Hyperhidrosis 50-100 units per hand, repeated every 6 months, as needed
Cerebral Palsy w/ Equinus Gait & Pediatric CP 4 Units/kg IM (up to 200 Units) divided into 2 injections in the affected leg every 12 weeks
Chronic Anal Fissures Recommended doses of up to 25 units, injected into the anal sphincter. Retreat every 3 months.
Laryngeal Dystonia Starting dose of 1.25-5 units into thyroarytenoid muscle. Dose titrated based on response & side effects. Retreat every 3 months
Hemifacial Spasms Recommended dose of 20 to 40 U, divided among affected muscles. Retreatment within 12 weeks
Oromandibular Dystonia 40 units injected into masseter and submentalis complex muscles every 12 weeks.
All other indications -unless otherwise specified Not to exceed a cumulative dose of 400 U (for one or more indications) every 12 weeks.

LENGTH OF AUTHORIZATION

Coverage will be provided for six months and may be renewed

Click here to view DOSAGE LIMITS

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

ADDITIONAL INFORMATION 

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

No controlled studies were found in the published literature that validate the use of onabotulinumtoxinA for the treatment or prevention of other conditions or diseases.

SOURCES

American Academy of Neurology and Child Neurology Society (January, 2010). Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Retrieved May 9, 2016 from the National Guideline Clearinghouse (NGC: 007677).

American Academy of Neurology. (2008, May). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Retrieved February 22, 2017 from http://www.neurology.org/content/70/19/1707.full.html.

American Academy of Neurology. (2008, May). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin in the treatment of spasticity (an evidence-based review). Retrieved February 22, 2017 from http://www.neurology.org/content/70/19/1691.full.html.

BlueCross BlueShield Association. Medical Policy Reference Manual. (10:2017). Botulinum toxin (5.01.05). Retrieved January 8, 2018 from BlueWeb.

BlueCross BlueShield Association. Medical Policy Reference Manual. (5:2017). Treatment of hyperhidrosis (8.01.19). Retrieved January 8, 2018 from BlueWeb.

Lexi-Comp Online. (2018). AHFS DI. OnabotulinumtoxinA. Retrieved January 23, 2018 from Lexi-Comp Online with AHFS.

Mazlan, M., Rajasegaran, S., Engkasan, J. P., Nawawi, O., Goh, K. J., Freddy, S .J. (2015). A double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-A for sialorrhea treatment in Asian adults with neurological diseases. Toxins, 2015(7), 3758-3770.

MICROMEDEX Healthcare Series. Drugdex Drug Evaluations. (2017, November). OnabotulinumtoxinA. Retrieved January 23, 2018 from MICROMEDEX Healthcare Series.

Møller, E., Pedersen, S. A., Vinicoff, P. G., Bardow, A., Lykkeaa, J., Svendsen, P., Bakke, M. (2015). OnabotulinumtoxinA treatment of drooling in children with cerebral palsy: a prospective, longitudinal open-label study. Toxins, 2015 (7), 2481-2493.

U. S. Food and Drug Administration. (2017, October). Center for Drug Evaluation and Research. Botox® (onabotulinumtoxinA). Retrieved January 23, 2018 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5302lbl.pdf. 

ORIGINAL EFFECTIVE DATE:  12/1998

MOST RECENT REVIEW DATE:  4/10/2018

ID_MRx

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.

 

 

DOSAGE LIMITS

Maximum billable units per dose and over time by indication as a Medical Benefit; 1 billable unit = 1 unit

DIAGNOSIS

BILLABLE UNITS

Per # days

Blepharospasm

200

30

Cervical Dystonia

300

84

Strabismus

100

84

Achalasia

100

168

Upper Limb Spasticity

400

84

Lower Limb Spasticity

400

84

Chronic Migraine

200

84

Severe Primary Axillary Hyperhidrosis

100

84

Sialorrhea

100

84

Neurogenic Bladder/Detrusor Overactivity

200

84

Overactive Bladder

100

84

Chronic Anal Fissures

100

84

Palmar Hyperhidrosis

200

168

Cerebral Palsy (CP) with Equinus Gait

200

84

Pediatric CP

200

84

Laryngeal Dystonia

100

84

Hemifacial Spasms

100

84

Oromandibular Dystonia

200

84

All other indications

400

84